Wegovy Cuts Heart Risk Even If People Don’t Lose Much Weight (1)

Novo Nordisk A/S’s blockbuster obesity drug Wegovy cut the risk of heart attacks and strokes irrespective of how much patients weighed, a study found, results that doctors said could drive more prescriptions for the medicine.

The heart benefit was seen across the board in the Wegovy patients, including people who were overweight but not obese, and in people who didn’t lose much weight, said John Deanfield, a professor of cardiology at University College London, who helped lead the trial.

The results mean millions of people would probably benefit from taking the drug, Deanfield said in a presentation at ...